Therapeutic antibodies towards immunomodulatory receptor-CD phase
| Reference number | |
| Coordinator | GENAGON THERAPEUTICS AB - GENAGON THERAPEUTICS AB, solna |
| Funding from Vinnova | SEK 900 000 |
| Project duration | June 2019 - August 2020 |
| Status | Completed |
| Venture | Innovative Startups |
| Call | Innovative Startups stage 2 - spring 2019 |
Important results from the project
The goal for the company was to investigate possible niches; therapeutic indications for the leading antibody. A separate objective was to investigate which variants of the antibody´s Fc part would be most suitable to develop. The company has now identified several specific disease indications that can be appropriate and was able to exclude others. A very interesting cell type in the immune system with specific expression of the target protein has been identified during the work. The cell type is of great interest to pharmaceutical companies in immuno-oncology.
Expected long term effects
The company has identified possible niches as well as a specific cell type to follow, to which disease indications it can lead. Furthermore, the company has developed tools to validate the selectivity of the developed antibodies. Additionally the company identified that the leading antibody with effector-neutral fc part was preferable.
Approach and implementation
The project was divided into identifying niches and which variants of the antibody would be further developed. The work was done both by CRO specialized in selected models and in-house. As the work progressed, several bonus effects could be achieved. The tools that were developed made it possible to identify more secreted proteins linked to the role of the target protein. The connections was previously unknown. The secreted proteins have important roles in the immune system. Furthermore, the target protein was enriched in a cell type of outmost importance in immuno-oncology.